Company intelligence / Profile preview

Themis Bioscience

Vienna, Vienna, Austriaorpha.net ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Successfully completed Phase 1 clinical trial for Chikungunya vaccine in 2014, started Phase 2 clinical trial for Chikungunya vaccine in 2016, and Phase 1 clinical trial for Zika vaccine in 2017. COVID-19 vaccine candidate was in pre-clinical development as of May 2020, with clinical studies planned to start later in 2020.

Therapeutic areas: Infectious Diseases
Modalities: Vaccinesimmunomodulation therapies
Industry: Biotech

Drug pipeline

1 asset

MV-CHIK

Phase 1

Indications: Chikungunya fever

Partnerships

Institut PasteurThe Center for Vaccine Research at the University of PittsburghCoalition for Epidemic Preparedness Innovations (CEPI)Merck & Co.

Beyond the preview

Go deeper on Themis Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Themis Bioscience.

Explore the full profile